Taylor_edit_Layout 1 03/12/2009 11:19 Page 40
Autoimmune Diseases Rheumatoid Arthritis
pegol in combination with MTX for the treatment of established RA such as those associated with joint arthroplasty and the need to pay
indicate significant reductions in work days lost, gains in productivity for carers. As yet, there are few long-term data that permit health
while at work as well as gains in ability to more fully engage in economic modelling that can reliably offset the expense of anti-TNF
household work and leisure activities. These welcome findings predict therapies themselves against the anticipated long-term savings. Such
a lowering of the indirect costs associated with RA, such as disability emerging data should, however, be taken into account when
benefits, as well as reduced direct costs of patient care over time, evaluating cost-effectiveness. n
1. Brennan FM, Chantry D, Jackson A, et al., Inhibitory effect of 2004;363:675–81. arthritis: five-year experience from the FIN-RACO
TNF alpha antibodies on synovial cell interleukin-1 17. Smolen JS, Van Der Heijde DM, St Clair EW, et al., Active- trial, Arthritis Rheum, 2005;52:36–41.
production in rheumatoid arthritis, Lancet, 1989;2:244–7. Controlled Study of Patients Receiving Infliximab for the 33. Puolakka K, Kautiainen H, Möttönen T, et al., Impact of initial
2. Butler DM, Maini RN, Feldmann M, et al., Modulation of Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) aggressive drug treatment with a combination of disease-
proinflammatory cytokine release in rheumatoid synovial Study Group. Predictors of joint damage in patients with modifying antirheumatic drugs on the development of work
membrane cell cultures. Comparison of monoclonal anti early rheumatoid arthritis treated with high-dose disability in early rheumatoid arthritis: A five-year
TNF-alpha antibody with the interleukin-1 receptor methotrexate with or without concomitant infliximab: results randomized follow-up trial, Arthritis Rheum, 2004;50:55–62.
antagonist, Eur Cytokine Netw, 1995;6:225–30. from the ASPIRE trial, Arthritis Rheum, 2006;54:702–10. 34. Smolen JS, Han C, van der Heijde D, et al., Infliximab
3. Haworth C, Brennan FM, Chantry D, et al., Expression of 18. Smolen JS, Han C, van der Heijde DM, et al., Active- treatment maintains employability in patients with early
granulocyte-macrophage colony-stimulating factor in Controlled Study of Patients Receiving Infliximab for the rheumatoid arthritis, Arthritis Rheum, 2006;54:716–22.
rheumatoid arthritis: regulation by tumor necrosis factor- Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) 35. Allaire SH, Meenan RF, Anderson JJ, The impact of
alpha, Eur J Immunol, 1991;21:2575–79. Study Group, Radiographic changes in rheumatoid arthritis rheumatoid arthritis on the household work performance of
4. Williams RO, Feldmann M, Maini RN, Anti-tumor necrosis patients attaining different disease activity states with women, Arthritis Rheum, 1991;34:669–78.
factor ameliorates joint disease in murine collagen-induced methotrexate monotherapy and infliximab plus 36. Habib G, Artul S, Ratson N, et al., Household work disability
arthritis, Proc Natl Acad Sci U S A, 1992;89:9784–8. methotrexate: the impacts of remission and tumour of arab housewives with rheumatoid arthritis, Clin Rheumatol,
5. Lipsky PE, van der Heijde DM, St Clair EW, et al., Infliximab necrosis factor blockade, Ann Rheum Dis, 2009;68:823–7. 2007;26:759–63.
and methotrexate in the treatment of rheumatoid arthritis. 19. St Clair EW, van der Heijde DM, Smolen JS, et al., Active- 37. Katz PP, Morris A, Yelin EH, Prevalence and predictors of
Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Controlled Study of Patients Receiving Infliximab for the disability in valued life activities among individuals with
Concomitant Therapy Study Group, N Engl J Med, Treatment of Rheumatoid Arthritis of Early Onset Study rheumatoid arthritis, Ann Rheum Dis, 2006;65:763–9.
2000;343:1594–1602. Group. Combination of infliximab and methotrexate therapy 38. Reisine ST, Goodenow C, Grady KE, The impact of
6. Weinblatt ME, Kremer JM, Bankhurst AD, et al., A trial of for early rheumatoid arthritis: a randomized, controlled rheumatoid arthritis on the homemaker, Soc Sci Med,
etanercept, a recombinant tumor necrosis factor receptor: trial, Arthritis Rheum, 2004;50:3432–3. 1987;25:89–95.
Fc fusion protein, in patients with rheumatoid arthritis 20. Emery P, Breedveld FC, Hall S, et al., Comparison of 39. Allaire S, Wolfe F, Niu J, et al., Contemporary prevalence and
receiving methotrexate, N Engl J Med, 1999;340:253–9. methotrexate monotherapy with a combination of incidence of work disability associated with rheumatoid
7. Weinblatt ME, Keystone EC, Furst DE, et al., Adalimumab, a methotrexate and etanercept in active, early, moderate to arthritis in the US, Arthritis Rheum, 2008;59:474–80.
fully human anti-tumor necrosis factor alpha monoclonal severe rheumatoid arthritis (COMET): a randomised, double- 40. Allaire S, Wolfe F, Niu J, et al., Evaluation of the effect of anti-
antibody, for the treatment of rheumatoid arthritis in blind, parallel treatment trial, Lancet, 2008;372:375–82. tumor necrosis factor agent use on rheumatoid arthritis
patients taking concomitant methotrexate: the ARMADA 21. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et work disability: The jury is still out, Arthritis Rheum,
trial, Arthritis Rheum, 2003;48:35–45. al., Clinical and radiographic outcomes of four different 2008;59:1082–9.
8. Keystone E, Heijde D, Mason D Jr, et al., Certolizumab pegol treatment strategies in patients with early rheumatoid 41. Han C, Smolen J, Kavanaugh A, et al., Comparison of
plus methotrexate is significantly more effective than arthritis (the BeSt study): a randomized, controlled employability outcomes among patients with early or long-
placebo plus methotrexate in active rheumatoid arthritis: trial, Arthritis Rheum, 2005;52:3381–90. standing rheumatoid arthritis, Arthritis Rheum,
findings of a fifty-two-week, phase III, multicenter, 22. Steinbrook R, Saying no isn’t NICE—the travails of Britain’s 2008;59:510–14.
randomized, double-blind, placebo-controlled, parallel-group National Institute for Health and Clinical Excellence, N Engl J 42. Bejarano V, Quinn M, Conaghan PG, et al., Effect of the early
study, Arthritis Rheum, 2008;58:3319–29. Med, 2008;359:1977–81. use of the anti-tumor necrosis factor adalimumab on the
9. Smolen J, Landewé RB, Mease P, et al., Efficacy and safety of 23. Mäkisara GL, Mäkisara P, Prognosis of functional capacity prevention of job loss in patients with early rheumatoid
certolizumab pegol plus methotrexate in active rheumatoid and work capacity in rheumatoid arthritis, Clin Rheumatol, arthritis, Arthritis Rheum, 2008;59:1467–74.
arthritis: the RAPID 2 study. A randomised controlled 1982;1:117–25. 43. Hoving JL, Bartelds GM, Sluiter JK, et al., Perceived work
trial, Ann Rheum Dis, 2009;68:797–804. 24. Wolfe F, Hawley DJ, The longterm outcomes of rheumatoid ability, quality of life, and fatigue in patients with rheumatoid
10. Keystone EC, Genovese MC, Klareskog L, et al., GO- arthritis: work disability: a prospective 18 year study of 823 arthritis after a 6-month course of TNF inhibitors:
FORWARD Study. Golimumab, a human antibody to tumour patients, J Rheumatol, 1998;25:2108–17. prospective intervention study and partial economic
necrosis factor {alpha} given by monthly subcutaneous 25. Callahan LF, Bloch DA, Pincus T, Identification of work evaluation, Scand J Rheumatol, 2009 Apr 1 (Epub ahead of
injections, in active rheumatoid arthritis despite disability in rheumatoid arthritis: physical, radiographic and print).
methotrexate therapy: the GO-FORWARD Study, Ann Rheum laboratory variables do not add explanatory power to 44. Halpern MT, Cifaldi MA, Kvien TK, Impact of adalimumab on
Dis, 2009;68:789–96. demographic and functional variables, J Clin Epidemiol, work participation in rheumatoid arthritis: comparison of an
11. Feldmann M, Maini RN, Lasker Clinical Medical Research 1992;45:127–38. open-label extension study and a registry-based control
Award, TNF defined as a therapeutic target for rheumatoid 26. Mau W, Bornmann M, Weber H, et al., Prediction of group, Ann Rheum Dis, 2009;68:930–37.
arthritis and other autoimmune diseases, Nature Medicine, permanent work disability in a follow-up study of early 45. Barra L, Pope JE, Payne M, Real-world anti-tumor necrosis
2003:9:1245–50. rheumatoid arthritis: results of a tree structured analysis factor treatment in rheumatoid arthritis, psoriatic arthritis,
12. Feldmann M, Maini RN, Anti-TNF therapy of rheumatoid using RECPAM, Br J Rheumatol, 1996;35:652–9. and ankylosing spondylitis: cost-effectiveness based on
arthritis: What have we learned? Ann Rev Immunol, 27. Reisine S, McQuillan J, Fifield J, Predictors of work disability number needed to treat to improve health assessment
2001:19:163–96. in rheumatoid arthritis patients. A five-year followup, Arthritis questionnaire, J Rheumatol, 2009;36:1421–8.
13. Isaacs JD, Antibody engineering to develop new Rheum, 1995;38:1630–37. 46. Kekow J, Moots RJ, Emery P, et al., Patient-reported
antirheumatic therapies, Arthritis Res Ther, 2009;11:225. 28. Verstappen SM, Bijlsma JW, Verkleij H, et al., Overview of outcomes improve with etanercept plus methotrexate in
14. Tracey D, Klareskog L, Sasso EH, et al., Tumor necrosis factor work disability in rheumatoid arthritis patients as observed active early rheumatoid arthritis and the improvement is
antagonist mechanisms of action: a comprehensive in cross-sectional and longitudinal surveys, Arthritis Rheum, strongly associated with remission: The COMET trial, Ann
review, Pharmacol Ther, 2008;117:244–79. 2004;51:488–97. Rheum Dis, 2009 Mar 16 (Epub ahead of print).
15. Breedveld FC, Weisman MH, Kavanaugh AF, et al., The 29. Yelin E, Henke C, Epstein W, The work dynamics of the 47. Osterhaus JT, Purcaru O, Richard L, Discriminant validity,
PREMIER study: a multicenter, randomized, double-blind person with rheumatoid arthritis, Arthritis Rheum, responsiveness and reliability of the rheumatoid arthritis-
clinical trial of combination therapy with adalimumab plus 1987;30:507–12. specific Work Productivity Survey (WPS-RA), Arthritis Res Ther,
methotrexate versus methotrexate alone or adalimumab 30. Burton W, Morrison A, Maclean R, et al., Systematic review 2009;11(3):R73.
alone in patients with early, aggressive rheumatoid arthritis of studies of productivity loss due to rheumatoid 48. Kavanaugh A, Smolen J, Emery P, et al., Certolizumab pegol
who had not had previous methotrexate treatment, Arthritis arthritis, Occup Med (Lond), 2006;56:18–27. added to methotrexate improves productivity at home and
Rheum, 2006;54:26–37. 31. Mittendorf T, Dietz B, Sterz R, et al., Personal and economic in the workplace in patients with active rheumatoid
16. Klareskog L, van der Heijde D, de Jager JP, et al., TEMPO (Trial burden of late-stage rheumatoid arthritis among patients arthritis, Arthritis Care Res, 2009; in press.
of Etanercept and Methotrexate with Radiographic Patient treated with adalimumab: An evaluation from a patient’s 49. Hazes JM, Purcaru O, Coteur G, Mease PJ, Fatigue reduction
Outcomes) study investigators. Therapeutic effect of the perspective, Rheumatology (Oxford), 2008;47:188–93. and physical function improvements associated with
combination of etanercept and methotrexate compared 32. Puolakka K, Kautiainen H, Möttönen T, et al., Early increased productivity at work and at home in rheumatoid
with each treatment alone in patients with rheumatoid suppression of disease activity is essential for maintenance arthritis patients, Ann Rheum Dis, 2008;67(Suppl. II):79.
arthritis: double-blind randomised controlled trial, Lancet, of work capacity in patients with recent-onset rheumatoid
40 EUROPEAN MUSCULOSKELETAL REVIEW
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108  |  Page 109  |  Page 110  |  Page 111  |  Page 112  |  Page 113  |  Page 114  |  Page 115  |  Page 116